This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Pharma Cinq, LLC. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Michael Kevin Bamat, Inventor of an Amorphous Uridine Triacetate Formulation.
Introduction
Michael Kevin Bamat is an inventor associated with Potomac, Maryland, and Pharma Cinq, LLC. His patent work concerns pharmaceutical formulation, particularly an amorphous dispersion of uridine triacetate.
Latest Patents
Bamat is named on one patent, titled “Uridine Triacetate Amorphous Formulation.” The patent describes a dispersion of amorphous uridine triacetate in Hypromellose Acetate Succinate-MG, optionally combined with Copovidone. The formulation is designed to support high uridine loading, good stability, and oral bioavailability. Bamat’s record includes 1 patent.
Career Highlights
Bamat’s listed work with Pharma Cinq, LLC, connects his inventive activity with pharmaceutical development. His patent focuses on formulation properties intended to support the delivery of uridine triacetate.
Collaborations
The provided information lists Jeffrey A. Miller and Yihong Qiu as Bamat’s coworkers. Their names are associated with his professional context, though specific roles in the patent are not stated here.
Conclusion
Michael Kevin Bamat’s patent activity centers on an amorphous uridine triacetate formulation designed for high loading, stability, and oral bioavailability.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile